Funapide

Funapide
Systematic (IUPAC) name
(7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
Clinical data
Routes of
administration		 Oral, topical
Identifiers
CAS Number 1259933-16-8
ATC code None
PubChem CID 49836093
ChemSpider 34500834
Chemical data
Formula C22H14F3NO5
Molar mass 429.34547 g/mol

Funapide (INN) (former developmental code names TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals in partnership with Teva Pharmaceutical Industries for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.[1][2][3][4] It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker.[1][2][4] Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.[1][3]

See also

References

  1. 1 2 3 Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.
  2. 1 2 Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0.
  3. 1 2 Xenon Pharma. "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders".
  4. 1 2 Xenon Pharma (2012). "Teva and Xenon Announce Teva’s World Wide License of Xenon’s Pain Drug XEN402".


This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.